A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Siegall has been CEO of Seagen for two decades, taking the helm of the company four years after co-founding it in 1998, and building it into a biotech bellwether with four drugs on the market and ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

To a lesser extent, there were fourth-quarter growth contributions from the legacy Seagen oncology-drug portfolio, the Vyndaqel family of heart-disease drugs, and higher Paxlovid sales year over ...

In 2023, Pfizer paid $43 billion to acquire Seagen, a large biopharma company focused on cancer treatments. That acquisition has given management confidence that it can produce as many as eight ...

A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year. Baker Bros. Advisors, a hedge-fund firm run by ...

The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 4+ companies and 4+ ...

Pfizer's planned debt sale this week, to help fund its acquisition of rival drugmaker Seagen, will rank among the largest individual corporate bond sales in U.S. history. In a filing with the U.S ...

NEW YORK: Pfizer Inc’s proposed US$43bil (RM195bil) takeover of Seagen Inc will face an investigation from the European Union’s (EU) merger enforcer, as the bloc continues to scrutinise large ...

Recently, Pfizer has concentrated on expanding its oncology segment, enhanced by the March 2023 acquisition of Seagen. This focus on oncology highlights the importance of research and development ...

Detailed price information for Verizon Communications Inc (VZ-N) from The Globe and Mail including charting and trades.